Company intelligence / Profile preview

Synolis VA

Plan-les-Ouates, Geneva, Switzerland

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Aptissen is a Swiss medical technology company specializing in the development and commercialization of injectable biopolymers for musculoskeletal disorders. The company's flagship product, Synolis VA, is a unique visco-antalgic solution combining high-concentration hyaluronic acid with sorbitol to treat osteoarthritis by providing rapid pain relief and restoring joint mobility. Spun off from Anteis in 2013, Aptissen focuses on innovative solutions in viscosupplementation and regenerative medicine. The company maintains a global presence, distributing its orthopedic and rheumatology products in numerous international markets.

Therapeutic areas: Rheumatology
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Synolis VA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synolis VA.

Explore the full profile